Nonmelanoma Skin Cancers, Immunotherapies, and Role of Dermatology Clinicians: A Care Team Forum®

Program Overview

The advent of immunotherapy has transformed dermatologic care, offering hope to patients with advanced NMSC. As the treatment armamentarium expands, clinicians must carefully weigh evolving data in order to optimize outcomes in BCC and CSCC.

Join us for this live webstream to hear our interprofessional expert panel offer privileged insights into evidence-based strategies for the identification of high-risk disease, selection of checkpoint inhibitors, and the management of immune-related adverse events. Uniquely, this panel discussion also features an experienced patient who will augment these insights with teaching moments from their treatment journey.

Credit Expired

Target Audience

This activity is intended for dermatology and medical oncology clinicians (MD/DO/NP/PA) and all of those who manage patients with advanced nonmelanoma skin cancer (NMSC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify high-risk patients with nonmelanoma skin cancer (NMSC) based on current staging systems, risk factors, and guidelines
  • Select appropriate checkpoint inhibitors in the management of patients with advanced NMSC
  • Integrate the unique roles and responsibilities of the interprofessional care team when managing patients with advanced NMSC

Activity Faculty

Vishal Anil Patel, MD, FAAD, FACMS (Chair)

Director, Cutaneous Oncology, GW Cancer Center
Director, Dermatologic Surgery, GW Department of Dermatology
Assistant Professor, Dermatology & Hematology/Oncology
Washington, DC

David M. Miller, MD, PhD, FAAD

Medical Oncologist, Dermatologist
Massachusetts General Hospital
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Department of Medicine, Division of Hematology/Oncology
Department of Dermatology
Massachusetts General Cancer Center
Boston, MA

Krista M. Rubin, MS, RN, FNP-BC

Nurse Practitioner, Center for Melanoma
Massachusetts General Hospital
Boston, MA

Subscribe

Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources